What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus
You may also be interested in...
Bioequivalence Testing Is First Step In China’s Pharma Industry Upgrade – RDPAC
Time is tight for China to complete an ambitious generic bioequivalence testing schedule, and the stakes couldn’t be higher for the industry, a top executive of the leading trade association in China says.
Bioequivalence Testing Is First Step In China’s Pharma Industry Upgrade – RDPAC
Time is tight for China to complete an ambitious generic bioequivalence testing schedule, and the stakes couldn’t be higher for the industry, a top executive of the leading trade association in China says.
Insider Analysis From Asia Pacific Bio Intelligence LLC On China State FDA’s Medical Device Regulations
For China’s State FDA, 2011 was a banner year, with regulations released on good manufacturing practices for both drugs and devices. Multinational companies should take notice and be sure their operations are in compliance.